Effect of intravenous morphine sulfate and intranasal dexmedetomidine on Patients' Pain

Comparison of analgesic effects and morphine consumption of intravenous morphine sulfate and intranasal dexmedetomidine with intravenous morphine sulfate in patients with extremity fractures presented in emergency departments

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111114008104N15

Enrollment

Registered

2019-01-02

Start date

2019-01-05

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extremity fracture. Pathological fracture, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients will receive intravenous morphine sulfate at a dose of 5 mg plus intranasal dexmedetomidine 10 mg per kg of body weight. Intervention 2: Control group: Pat

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Organ trauma leading to acute fractures Patients over the eighteen years old

Exclusion criteria

Exclusion criteria: Loss of consciousness Chronic kidney and coronary artery disease Pregnancy Drinking alcohol and drugs

Design outcomes

Primary

Measure	Time frame
Severity of pain after prescribing. Timepoint: After 15, 30, 60 and 120 minutes after using the drug. Method of measurement: From 1 to 10 (Based on numerical scale).;Total dosage of the drug. Timepoint: After the end of treatment. Method of measurement: Based on the information in the patient file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Amin Zare

Iran University of Medical Sciences

mazare74@yahoo.com+98 21 8670 2503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026